Published 4 days ago • loading... • Updated 3 days ago

Direct Digital Holdings Reports Q4 & Full-Year 2024 Financial Results

On March 27, 2025, Direct Digital Holdings, Inc. Announced its Q4 and full-year financial results for the period ended December 31, 2024, during which management announced they would host a conference call at 5:00 PM ET.
The company's Q4 results were in line with revised revenue guidance, despite challenges faced during the year stemming from a defamatory article that led to the suspension of a large customer, impacting sell-side revenue.
Full-Year revenue for 2024 reached $62.3 million, while Q4 revenue was $9.1 million, representing a 78% decrease compared to the same period in 2023, and the company continued to diversify its customer base with leading sell-side partners and buy-side customers in new verticals.
Despite a net loss of $9.3 million in fiscal year 2024, the company is implementing a lower cost structure and optimizing performance, as CFO Diana Diaz stated, "As we continue to refocus the company, our lower cost structure, optimized performance and focus on driving efficiencies across the business are key to our accelerated path to return to profitability."
Direct Digital Holdings is reiterating its full-year revenue guidance of $90 million to $110 million for FY 2025, while acknowledging substantial doubt about its ability to continue as a going concern and the potential impact of various factors, including ineligibility to file short-form registration statements and failure to satisfy Nasdaq Capital Market listing standards.

Insights by Ground AI

Does this summary seem wrong?

43 Articles

All

Left

Center

Right

Hastings Tribune

Center

Bio-Path Holdings Reports Full Year 2024 Financial Results

HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for…

3 days ago

Read Full Article

The Herald Journal

+4 Reposted by 4 other sources

Center

Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended…

4 days ago

Read Full Article